SITETRACKER,-INC.
13.1.2021 09:02:37 CET | Business Wire | Press release
Sitetracker , the global standard for managing high-volume projects for critical infrastructure owners and operators such as Vodafone, Ericsson, and British Telecom, is proud to announce they received the Scale-Up of the Year (2020) crown by Vodafone at their supplier awards.
Hosted virtually for the first time, the Vodafone Suppliers Awards are annually held in Luxembourg. With categories including Supplier of the Year, Sustainable Supply Chain, and Health and Safety, this is the first year Vodafone has recognized Scale-Ups in their own category.
“It is an honor to have Vodafone recognize us alongside industry giants like Nokia, Accenture, and Cisco,” said David George, SVP of International at Sitetracker. “It is a testament to the partnership we have forged and the determination of both our teams who strive for success, day in and day out.”
Before Sitetracker, businesses involved in telecom infrastructure deployment and maintenance relied on disparate point solutions, inhouse tools, or antiquated industry incumbents. Now, with Sitetracker’s next-generation platform, re-work, delayed closeouts, and shrinking margins are a thing of the past. From mobile to fixed, tower use cases and more, Sitetracker ensures seamless interactions between the broader ecosystem of vendors and contractors. With unmatched flexibility and scale, Sitetracker enables companies like Vodafone to take advantage of the latest advancements in AI and Predictive Analytics to speed up core operational workflows.
“Thank you to team Vodafone for honoring us with this coveted award,” said Giuseppe Incitti, CEO at Sitetracker. “Over the past 2 years, we have worked with multiple Vodafone groups to help them realize their ambitions to find operational excellence. This award is clear recognition of the progress we have made and the foundation we have built together.”
Sitetracker, Inc. powers the successful deployment of critical infrastructure. As the global standard for managing high-volume projects, the Sitetracker Platform enables growth-focused innovators to optimize the entire asset lifecycle. From the field to the C-suite, Sitetracker enables stakeholders to optimize how they plan, deploy, maintain, and grow their capital asset portfolios. Market leaders in the telecommunications, utility, smart cities, and energy industries — such as Vodafone, Fortis, Alphabet, British Telecom, and Ericsson — rely on Sitetracker to manage millions of sites and projects representing over $23 billion of portfolio holdings globally. For more information, visit www.sitetracker.com .
Vodafone is a leading technology communications company keeping society connected and building a digital future for everyone. Vodafone is focused on two scaled and differentiated regional platforms in Europe and Africa. We operate mobile and fixed networks in 22 countries and partner with mobile networks in 48 more. As at 30 June 2020 we had over 300m mobile customers, more than 27m fixed broadband customers and over 22m TV customers. We connect for a better future. We are optimistic about how technology and connectivity can enhance the future and improve people’s lives. Through our business, we aim to build a digital society that enhances socio-economic progress, embraces everyone and does not come at the cost of our planet. That is why we have committed to improve one billion lives and halve our environmental impact by 2025. For more information, please visit: www.vodafone.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005006/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
